Inozyme Pharma (INZY) Competitors $4.00 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY vs. AUPH, ARDX, ELVN, VERV, NAGE, DYN, CDTX, COLL, BGM, and PHVSShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Collegium Pharmaceutical (COLL), BGM Group (BGM), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. Its Competitors Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Dyne Therapeutics Cidara Therapeutics Collegium Pharmaceutical BGM Group Pharvaris Inozyme Pharma (NASDAQ:INZY) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Which has more volatility & risk, INZY or AUPH? Inozyme Pharma has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Is INZY or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 16.11% compared to Inozyme Pharma's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Inozyme PharmaN/A -159.93% -82.48% Aurinia Pharmaceuticals 16.11%14.27%9.93% Does the media favor INZY or AUPH? In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Inozyme Pharma. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 2 mentions for Inozyme Pharma. Aurinia Pharmaceuticals' average media sentiment score of 1.25 beat Inozyme Pharma's score of 0.93 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inozyme Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend INZY or AUPH? Inozyme Pharma currently has a consensus price target of $11.75, indicating a potential upside of 193.75%. Aurinia Pharmaceuticals has a consensus price target of $11.50, indicating a potential upside of 30.68%. Given Inozyme Pharma's higher possible upside, equities analysts clearly believe Inozyme Pharma is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inozyme Pharma 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in INZY or AUPH? 88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 12.2% of Inozyme Pharma shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, INZY or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Inozyme Pharma. Inozyme Pharma is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInozyme PharmaN/AN/A-$102.02M-$1.69-2.37Aurinia Pharmaceuticals$235.13M5.06$5.75M$0.2831.43 SummaryAurinia Pharmaceuticals beats Inozyme Pharma on 11 of the 15 factors compared between the two stocks. Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.25M$2.94B$5.55B$9.09BDividend YieldN/A2.45%5.07%4.03%P/E Ratio-2.3720.8528.2520.31Price / SalesN/A295.87433.2199.68Price / CashN/A41.0526.2427.98Price / Book4.447.638.125.50Net Income-$102.02M-$55.05M$3.19B$250.38M7 Day PerformanceN/A8.43%3.62%4.79%1 Month Performance0.25%8.14%5.98%9.59%1 Year Performance-22.33%1.62%29.39%16.41% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma3.257 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750AUPHAurinia Pharmaceuticals3.0489 of 5 stars$7.47-1.6%$11.50+53.9%+56.9%$1.03B$235.13M26.68300Positive NewsARDXArdelyx4.1234 of 5 stars$4.35+1.9%$10.89+150.3%-23.8%$1.02B$333.61M-19.7790Analyst RevisionELVNEnliven Therapeutics2.8189 of 5 stars$19.59-5.5%$41.20+110.3%-9.3%$1.02BN/A0.0050Insider TradeVERVVerve Therapeutics3.0286 of 5 stars$11.16-1.1%$14.57+30.6%+63.9%$1.01B$59.61M-5.29110NAGENiagen Bioscience1.3447 of 5 stars$12.44-2.1%$19.50+56.8%+333.0%$1.00B$99.60M141.22120DYNDyne Therapeutics3.5958 of 5 stars$8.18-6.6%$41.13+402.8%-79.2%$995.72MN/A-2.28100Analyst ForecastHigh Trading VolumeCDTXCidara Therapeutics4.1206 of 5 stars$48.30-1.0%$57.14+18.3%+340.2%$983.59M$1.27M-1.6490Analyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.0321 of 5 stars$30.90+1.8%$43.75+41.6%+2.3%$975.20M$631.45M25.33210Positive NewsBuyback AnnouncementBGMBGM GroupN/A$10.00-0.3%N/AN/A$975.14M$25.10M0.00298PHVSPharvaris1.5268 of 5 stars$18.00-3.2%$36.20+101.1%+33.8%$972.60MN/A0.0030News Coverage Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives Ardelyx Alternatives Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Niagen Bioscience Alternatives Dyne Therapeutics Alternatives Cidara Therapeutics Alternatives Collegium Pharmaceutical Alternatives BGM Group Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INZY) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
